Status:
COMPLETED
Glucagon Resistance in Patients With NAFLD
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Danish Council for Independent Research
Conditions:
Non-Alcoholic Fatty Liver Disease
Non-alcoholic Steatohepatitis
Eligibility:
All Genders
38-68 years
Phase:
NA
Brief Summary
The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Moreover, they...
Eligibility Criteria
Inclusion
- BMI \> 28 kg/m2
- steatosis FF% \> 5,6% on MR spectroscopy for NAFLD and NASH groups
Exclusion
- active smoking
- pregnancy
- comorbidity other than hypertension and hyperlipidemia
- participation in other radioactive isotope studies within the past 3-5 months (depending on radiation dose)
- blood donation (within 3 months)
Key Trial Info
Start Date :
October 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 18 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04042142
Start Date
October 5 2019
End Date
August 18 2022
Last Update
November 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Danmark, Denmark, 8200